Program in Health Services and Systems Research, Duke-NUS Medical School, Singapore, Singapore.
Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore.
Qual Life Res. 2018 Sep;27(9):2321-2327. doi: 10.1007/s11136-018-1900-x. Epub 2018 Jun 5.
The purpose of the study was to assess the impact of axial spondyloarthritis (axSpA) on patients' quality of life (QoL) compared to patients with moderate to end-stage chronic kidney disease (CKD).
We conducted secondary analysis of QoL data obtained from patients with axSpA and CKD from 2011 to 2014. QoL was assessed using the SF-36 version 2 and KDQoL-SF for patients with axSpA and CKD, respectively. Patients with CKD were subcategorized to CKD-pre-dialysis, hemodialysis (CKD-HD) and peritoneal dialysis (CKD-PD). Linear regression was used to compare QoL between patients with axSpA and CKD after adjusting for age, gender, ethnicity, education level, and marital status.
A total of 765 patients (mean age 54.6, 63.0% males, 69.0% Chinese) were analyzed, of which 188 (24.5%) had axSpA. Patients with axSpA had poorer SF-36 bodily pain (BP) scores (axSpA: reference; CKD-pre-dialysis β: 11.04, p < 0.001; CKD-HD β: 9.52, p < 0.001; CKD-PD β: 10.35, p < 0.001) and higher general health scores (axSpA: reference; CKD-pre-dialysis β: - 7.87, p < 0.001; CKD-HD β: - 7.14, p < 0.001, CKD-PD β: - 7.25, p < 0.001) as compared to patients with CKD. Generally, patients with axSpA had poorer SF-36 scores than patients with CKD-pre-dialysis and similar SF-36 scores compared to patients with CKD-HD or CKD-PD.
The burden of axSpA on QoL is not trivial and is comparable to patients with CKD-HD or CKD-PD.
本研究旨在评估与患有中末期慢性肾脏病（CKD）的患者相比，中轴型脊柱关节炎（axSpA）对患者生活质量（QoL）的影响。
我们对 2011 年至 2014 年 axSpA 和 CKD 患者的 QoL 数据进行了二次分析。分别使用 SF-36 版本 2 和 KDQoL-SF 评估 axSpA 和 CKD 患者的 QoL。将 CKD 患者分为 CKD 透析前、血液透析（CKD-HD）和腹膜透析（CKD-PD）。在校正年龄、性别、种族、教育水平和婚姻状况后，使用线性回归比较 axSpA 和 CKD 患者的 QoL。
共分析了 765 名患者（平均年龄 54.6 岁，63.0%为男性，69.0%为中国人），其中 188 名（24.5%）患有 axSpA。axSpA 患者的 SF-36 身体疼痛（BP）评分较差（axSpA：参考；CKD 透析前 β：11.04，p<0.001；CKD-HD β：9.52，p<0.001；CKD-PD β：10.35，p<0.001），一般健康评分较高（axSpA：参考；CKD 透析前 β：-7.87，p<0.001；CKD-HD β：-7.14，p<0.001，CKD-PD β：-7.25，p<0.001）与 CKD 患者相比。一般来说，axSpA 患者的 SF-36 评分比 CKD 透析前患者差，与 CKD-HD 或 CKD-PD 患者的 SF-36 评分相似。
axSpA 对 QoL 的负担不小，与 CKD-HD 或 CKD-PD 患者相当。
